Acurx Pharmaceuticals, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

ISSUANCE OF EQUITY INTERESTS (Details)

ISSUANCE OF EQUITY INTERESTS (Details) - USD ($)									1 Months Ended	6 Months Ended
ISSUANCE OF EQUITY INTERESTS (Details) - USD ($)	Jun. 20, 2025	Jun. 17, 2025	May 08, 2025	Mar. 06, 2025	Jan. 06, 2025	Nov. 15, 2023	May 18, 2023	Jul. 27, 2022	Jan. 31, 2024	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2024	Jun. 23, 2021
Equity
Common stock, Authorized (in shares)										200,000,000		200,000,000	200,000,000
Common stock, Outstanding (in shares)										1,470,352		851,534
Common stock, Issued (in shares)										1,470,352		851,534
Common stock par value (in dollars per share)										$ 0.001		$ 0.001
Warrants exercised (in shares)										252,022
Affiliate Investors \| Series B warrants
Equity
Warrants exercised (in shares)									2,961
Proceeds from warrant exercises									$ 200,000
Underwriter option \| Series E warrants
Equity
Shares issued (in shares)					7,389
Warrant exercise price (in dollars per share)					$ 25.38
Underwriter option \| Series F warrants
Equity
Shares issued (in shares)				8,234
Warrant exercise price (in dollars per share)				$ 10
Warrants term				24 months
Registered Direct Offering
Equity
Proceeds from stock issue							$ 4,000,000	$ 4,200,000
Registered Direct Offering \| Pre-funded warrants
Equity
Shares issued (in shares)							36,574	6,538
Registered Direct Offering \| Series A warrants
Equity
Shares issued (in shares)								64,499
Registered Direct Offering \| Series B warrants
Equity
Shares issued (in shares)								64,499
Registered Direct Offering \| Series C warrants
Equity
Shares issued (in shares)							66,667
Registered Direct Offering \| Series D warrants
Equity
Shares issued (in shares)							66,667
January 2025 Registered Direct Offering
Equity
Shares issued (in shares)					123,153
Share sales price (in dollars per share)					$ 20.3
Proceeds from stock issue					$ 2,500,000
Net proceeds stock issuance					$ 2,100,000
Registered Direct Offering costs										$ 85,419
January 2025 Registered Direct Offering \| Series E warrants
Equity
Shares issued (in shares)					123,153
Warrant exercise price (in dollars per share)					$ 18
Warrants term					5 years
January 2025 Registered Direct Offering \| Affiliate Investors
Equity
Shares issued (in shares)					8,374
January 2025 Registered Direct Offering \| Affiliate Investors \| Series E warrants
Equity
Shares issued (in shares)					8,374
January 2025 Registered Direct Offering \| Investor
Equity
Shares issued (in shares)					114,779
January 2025 Registered Direct Offering \| Investor \| Series E warrants
Equity
Shares issued (in shares)					114,779
March 2025 Registered Direct Offering
Equity
Shares issued (in shares)				107,500
Share sales price (in dollars per share)				$ 8
Proceeds from stock issue				$ 1,100,000
Net proceeds stock issuance				$ 900,000
Registered Direct Offering costs										$ 56,163
March 2025 Registered Direct Offering \| Pre-funded warrants
Equity
Shares issued (in shares)				29,750
Warrant exercise price (in dollars per share)				$ 7.998
March 2025 Registered Direct Offering \| Series F warrants
Equity
Shares issued (in shares)				411,750
Warrant exercise price (in dollars per share)				$ 8
Warrants term				24 months
At the Market Offering
Equity
Shares issued (in shares)											62,743
Share sales price (in dollars per share)											$ 76
Proceeds from stock issue											$ 4,800,000
Net proceeds stock issuance											$ 4,600,000
Aggregate offering price						$ 17,000,000
Equity Line of Credit Purchase Agreement
Equity
Shares issued (in shares)			72,000
Share sales price (in dollars per share)			$ 9.85
Proceeds from stock issue			$ 709,140
Net proceeds stock issuance			610,262
Aggregate value of shares committed for purchase			$ 12,000,000
Equity Line of Credit Purchase Agreement \| Lincoln Park Capital Fund
Equity
Shares issued (in shares)			44,963
Non-cash issuance costs of ELOC agreement			$ 360,000
Warrant Inducement Agreement
Equity
Number of shares called by Warrant		222,272
Warrant exercise price (in dollars per share)		$ 12
Proceeds from warrant exercises		$ 2,700,000
Proceeds from stock issue		2,700,000
Net proceeds stock issuance		$ 2,500,000
Warrant Inducement Agreement \| Series A warrants
Equity
Number of shares called by Warrant		61,538
Warrant exercise price (in dollars per share)		$ 65
Warrant Inducement Agreement \| Series B warrants
Equity
Number of shares called by Warrant		27,400
Warrant exercise price (in dollars per share)		$ 65
Warrant Inducement Agreement \| Series C warrants
Equity
Number of shares called by Warrant		66,667
Warrant exercise price (in dollars per share)		$ 65.2
Warrant Inducement Agreement \| Series D warrants
Equity
Number of shares called by Warrant		66,667
Warrant exercise price (in dollars per share)		$ 65.2
Warrant Inducement Agreement \| Series G Warrants
Equity
Warrant exercise price (in dollars per share)		$ 8.5
Non-cash equity issuance costs	$ 4,527,245
Warrant Inducement Agreement \| Series G-1 Warrants
Equity
Shares issued (in shares)		311,180
Warrants term		5 years
Warrant Inducement Agreement \| Series G-2 Warrants
Equity
Shares issued (in shares)		133,363
Warrants term		5 years
Warrant Inducement Agreement \| H.C. Wainwright & Co.
Equity
Percentage of private placement offerings warrant coverage	7.00%
Warrant Inducement Agreement \| H.C. Wainwright & Co. \| Underwriter's Warrants
Equity
Shares issued (in shares)	13,336
Warrant exercise price (in dollars per share)	$ 15